INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.
Pavlakis N, Shitara K, Sjoquist K, Martin A, Jaworski A, Tebbutt N, Bang YJ, Alcindor T, O'Callaghan C, Strickland A, Rha SY, Lee KW, Kim JS, Bai LY, Hara H, Oh DY, Yip S, Zalcberg J, Price T, Simes J, Goldstein D.
Pavlakis N, et al. Among authors: bai ly.
J Clin Oncol. 2024 Oct 4:JCO2400055. doi: 10.1200/JCO.24.00055. Online ahead of print.
J Clin Oncol. 2024.
PMID: 39365958